JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - ALLOGENE THERAPEUTICS INC
Explicit Guidance:
- Alpha-3 (SemaCell) Primary Analysis: ABLA quality data generation and a favorable FDA outcome are anticipated in 2028, driven by the primary endpoint of Event-Free Survival (EFS).
- Alpha-3 Interim Analysis: A secondary analysis focusing on EFS is currently expected to occur in the middle of 2027.
- Autoimmune Program Timeline: Strategic decisions regarding dose expansion, conditioning regimens, and indication refinement are expected to be communicated via updates early in the new year (2027).
- Autoimmune Pivot: A transition toward Phase 2 studies and the development of a registrational evidence base is targeted for 2027.
Business-Segment Outlook:
- Alpha-3 Enrollment & Geography: Enrollment activity is projected to continue strong in 2026. The Asia-Pacific region is fully onboarded, with a goal to increase the total active site count from 85 to approximately 100 sites by the end of the current calendar year. European sites are scheduled to open in the first half of 2027.
- Site Composition: The mix of clinical sites is expected to shift toward a >50% academic balance compared to the historical 50/50 split, driven by the onboarding of highly active academic sites in Korea and Australia, though U.S. community site engagement remains high.
- Autoimmune Dose Escalation: The study is planned to escalate from 80 million cells to a 160 million cell dose level, with 320 million cells planned as a subsequent escalation tier pending safety validation.
- Market Expansion (Lymphoma): Management anticipates that the approval of Semacell will resolve the "treatment decision gap" associated with MRD positivity, potentially accelerating greater adoption of MRD testing in the lymphoma market (currently trending from 20% to 40% usage among physicians).
Market and Competitive Outlook:
- Competitive Landscape (Autoimmune): Allogene maintains a first-mover advantage as the only company with a dual-targeting CD19/CD70 CAR-T in autoimmune disease; peer companies are currently behind in the allogeneic space.
- Competitive Landscape (Lymphoma): Management anticipates minimal competitive impact on MRD positivity rates from emerging bispecifics (e.g., Epcoral + RCHOP), predicting that these complex, toxic regimens will see restricted uptake primarily in referral centers, while the bulk of the market (rank-and-file) will continue to receive R-CHOP or Polatuzumab R-CHOP.
- Target Population Dynamics: New frontline regimens are expected to impact the overall MRD positivity rate by only 5% to 10% across the board, preserving the total addressable market for Alpha-3.
- Market Access Disruption: Allogene expects to solve the current market constraint where only 15% to 20% of eligible U.S. patients receive CAR-T, by enabling outpatient delivery of allogeneic products in community practices.
Macro / Industry Outlook:
- Diagnostic Trends: The industry is witnessing substantive and rapid uptake of Minimal Residual Disease (MRD) testing, a trend expected to accelerate if Semacell receives approval as a downstream treatment option.
- Treatment Standard of Care: While bispecifics and RCHOP variants are viewed as positive outcomes for patients, the industry is expected to maintain a dual-track approach: complex, high-toxicity regimens for high-risk referral patients, and standard R-CHOP for the majority of community-treated patients.
- Immunology Research Evolution: The field is moving beyond simple peripheral B-cell depletion as a sole marker of efficacy, with increasing focus on tissue-level activity and specific B-cell subpopulations driving pathogenesis.
Strategic Initiatives:
- Alpha-3 Study Design: The trial is designed to demonstrate a hazard ratio of 0.5 (doubling of EFS) compared to the control arm. The study is event-driven and governed by a Data Safety Monitoring Board (DSMB).
- Autoimmune Program Flexibility: The study protocol allows for simultaneous dose escalation and cohort expansion of any regimen (Lupus, Myositis, Scleroderma) once deemed safe by an independent review team.
- Strategic Pivot Review: Management is evaluating a potential pivot in the autoimmune program, specifically reassessing the risk/benefit of the current flu-dara conditioning regimen given recent industry toxicity concerns, to refine the development strategy.
- Community-Centric Delivery: A key strategic initiative is validating the ability to administer allogeneic CAR-T in community settings (outpatient) without requiring hospitalization, steroids, or intensive care, thereby expanding patient access.
Risks and Headwinds to Outlook:
- DSMB Outcomes: The Alpha-3 interim analysis in 2027 could result in three scenarios: confirmation the study is on track, a recommendation to stop early for efficacy (which would trigger a registrational filing but limit further data collection), or a futility determination.
- Futility in Early Data: While management does not expect it, there remains a remote possibility the DSMB recommends stopping the Alpha-3 study for futility.
- Trial Integrity Constraints: If interim results are statistically significant, management may be forced to file based on that dataset alone because patient enrollment would likely cease once control arm outcomes are known to be inferior.
- Regulatory Uncertainty: The final filing strategy depends entirely on the magnitude of the interim result and the subsequent FDA dialogue.
- Safety Signals: Potential toxicity concerns regarding flu-dara conditioning in the autoimmune space could force a regimen change.
- Limited Data Access: The company operates under strict blindness protocols; management does not have access to blind efficacy data or specific safety dropouts until pre-specified analyses occur, limiting real-time decision-making on interim efficacy.
Management Tone on the Future:
- Confidence Level: High confidence in the positive outcome of Alpha-3, describing the safety profile as "extremely clean" and the efficacy differential as "very nice."
- Strategic Certainty: Management expresses certainty that the Alpha-3 study will lead to FDA approval and that the "disruptive" nature of the product will significantly expand market access.
- Competitive Stance: A confident and welcoming attitude toward early-phase studies by other companies, viewing them as validation of the "frontline consolidation" thesis rather than a threat, given Allogene's significant head start since 2023.
- Operational Momentum: Tone reflects optimism regarding enrollment speed, noting that the autoimmune program had no enrollment issues and currently has a "waiting list of patients."
Miscellaneous:
- Alpha-3 Control Arm Dynamics: The study compares Semacell against an observation control arm; patients randomized to the control arm are currently MRD positive.
- Autoimmune Mechanism: The dual-targeting CD19/CD70 design is intended to modulate B and T cells with a disproportionate effect on disorder outcomes by targeting immune synapse formation.
- Dose Strategy: Autoimmune dosing is proceeding at relatively low levels (starting at 20M cells) compared to oncology and peer allogeneic companies, with the next planned step at 160M cells.
- Data Safety: Safety is monitored in real-time with a 24-hour turnaround for significant events; no safety issues have been flagged in Alpha-3 to date.
- Company
- ALLOGENE THERAPEUTICS INC
- Keywords
- ALLOGENE THERAPEUTICS INC